Kavindra Nath, Ph.D.

faculty photo
Research Assistant Professor of Radiology
Department: Radiology

Contact information
B6 Blockley Hall
423 Guardian Drive
Perelman School of Medicine
Department of Radiology
University of Pennsylvania
Philadelphia, PA 19104
Education:
M.Sc. (Biochemistry)
Dr. Ram Manohar Lohia Avadh University, Faizabad, UP, India, 2002.
Ph.D. (Magnetic Resonance Imaging and Spectroscopy)
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow UP, India, 2008.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Selective acidification and de-energization of cancers via inhibition of monocarboxylate transporters (MCTs), mitochondrial pyruvate carrier (MPC), and Electron Transport Chain (ETC).
Development of a safe and reproducible method to selectively acidify and de-energize the human cancers. Specifically, we seek to employ the natural tendency of cancers to convert glucose to lactate as a method for selective intracellular acidification, which is known to potentiate tumor response to chemotherapy, radiation therapy, hyperthermia, and photodynamic therapy. In vivo 31P and 1H Magnetic Resonance Spectroscopy demonstrated that human cancer xenografts such as melanoma, breast, prostate and ovarian in immunosuppressed mice treated with MCT, MPC and ETC inhibitor, lonidamine, exhibit a sustained and tumor-selective decrease in pH, bioenergetics and increase in lactate and subsequent sensitization to nitrogen mustards, doxorubicin and radiation therapy.
Expertise
Mouse Xenograft development, tumor cells studies, drug delivery, metabolomics, and tumor micro-environment modulation.
Surface coil development to perform MRI/MRS studies on subcutaneous xenografts in mice.
1H, 31P, 13C Spectroscopy, T1, T2, Diffusion weighted and Dynamic Contrast Enhanced (DCE) MRI of mouse xenografts.
Diffusion tensor imaging and proton magnetic resonance spectroscopy of patients with various intracranial mass lesions.
Measurement of test-retest reproducibility of SUV (Subsidized Uptake Value) on PET under clinical practice conditions in cancer patients.

Selected Publications

*Nath K, Roman J, Nelson DS, Guo L, Lee SC, Orlovskiy S, Muriuki K, Heitjan DF, Leeper DB, Blair IA, Putt ME, Glickson JD: Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin. Scientific Reports 8(14654 ), October 2 2018 *Corresponding Author.

Zhou R, Bagga P, Nath K, Hariharan H, Mankoff D and Reddy R: Glutamate-weighted Chemical Exchange Saturation Transfer (GluCEST) Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple Negative Breast Cancer. Cancer Research doi: 10.1158/0008-5472(CAN-17-3988), 2018, Aug 2 [Epub ahead of print]

Xu HN, Feng M, Nath K, Nelson DS, Roman J, Zhao H, Lin Z, Glickson JD, Li LZ: Optical Redox Imaging of Lonidamine Treatment Response of Melanoma Cells and Xenografts. Molecular Imaging and Biology DOI: 10.1007/s11307-018-1258-z, 2018 [Epub ahead of print]

*Nath K, Nelson DS, Roman J, Putt ME, Lee SC, Leeper DB, Glickson JD : Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide. Anticancer Research 37(7): 3413-3421, July 2017. *Corresponding Author.

Choi H, Liu T, Nath K, Zhou R, Chen IW: Peptide nanoparticle with pH-sensing cargo solubility enhances cancer drug efficiency. Nano Today 13: 15-22, 22 March 2017.

*Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, Roman J, Zhou R, Leeper DB, Halestrap AP, Blair IA, Glickson JD: Mechanism of antineoplastic activity of lonidamine. BBA Reviews on Cancer 1866(2): 151-162, 2016. *Corresponding Author.

*Nath K, Nelson DS, Putt ME, Leeper DB, Garman B, Nathanson KL, Glickson JD: Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. PLoS One 11(6), June 2016. *Corresponding Author.

Shestov AA, Lee SC, Nath K, Guo L, Nelson DS, Roman JC, Leeper DB, Wasik MA, Blair IA, Glickson JD: 13C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism. Frontiers in Oncology 6(135), 2016.

Nancolas B, Guo L, Zhou R, Nath K, Nelson DS, Leeper DB, Blair IA, Glickson JD, Halestrap AP: The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochemical Journal 473(7): 929-36, 2016.

Guo L, Shestov AA, Worth AJ, Nath K, Nelson DS, Leeper DB, Glickson JD, Blair IA: Inhibition of mitochondrial complex II by the anti-cancer agent lonidamine. Journal of Biological Chemistry 291(1): 42-57, 2016.

back to top
Last updated: 10/02/2018
The Trustees of the University of Pennsylvania